SCHEMBL5687409

SCHEMBL5687409

Cc1ccc(Cc2ccc(OC(=O)N3CCC(Sc4nnnn4-c4ccc(C(=O)O)cc4)CC3)cc2)nc1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.40
MEN1 O00255 3/20 0.40
HPGD P15428 3/20 0.39
ALDH1A1 P00352 6/20 0.38
MAPT P10636 3/20 0.38
TP53 P04637 3/20 0.38
LMNA P02545 2/20 0.38
HTT P42858 2/20 0.38
GFER P55789 1/20 0.38
PPARG P37231 1/20 0.36
NPSR1 Q6W5P4 2/20 0.36
TSHR P16473 2/20 0.35
MAPK1 P28482 1/20 0.35
CCR6 P51684 1/20 0.34
CACNA1B Q00975 1/20 0.34
APBA1 Q02410 1/20 0.34
ALPL P05186 1/20 0.34
ALPG P10696 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5688544 0.93 KMT2A (0.39) KMT2AMEN1HPGDALDH1A1MAPT
SCHEMBL5688997 0.89 LIPE (0.43) KMT2AMEN1HPGDALDH1A1MAPT
SCHEMBL5687843 0.89 KMT2A (0.41) KMT2AMEN1HPGDALDH1A1MAPT
SCHEMBL5687655 0.88 HPGD (0.44) KMT2AMEN1HPGDALDH1A1MAPT
SCHEMBL5688137 0.86 NPSR1 (0.41) KMT2AMEN1HPGDALDH1A1MAPT
SCHEMBL5690077 0.86 ALDH1A1 (0.35) ALDH1A1TSHRSMN1; SMN2
SCHEMBL5688785 0.84 NPY2R (0.35) MAPTMAPK1
SCHEMBL5688328 0.84 NPSR1 (0.41) KMT2AMEN1HPGDALDH1A1MAPT
SCHEMBL5690600 0.84 KMT2A (0.41) KMT2AMEN1HPGDALDH1A1MAPT
SCHEMBL5688370 0.83 SMO (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160851-A1 Substituted piperidine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636207-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111032-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
US-20060160851-A1 Substituted piperidine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US disclosed
EP-1636207-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111032-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160851-A1 Substituted piperidine carbamates LIPE, PNLIP, LIPC KMT2A 1520/4885MEN1 2729/4885HPGD 1372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.